We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In addition to an 87 percent drop in risk of hospitalization and death by day 28, the results also showed an 81 percent reduction in risk of medical visits due to COVID-19 compared with placebo. Read More
Gilead Sciences’ antiviral drug Veklury (remdesivir) appeared to reduce hospitalizations and death by 87 percent in patients with new cases of COVID-19, according to data just released by the company. Read More
The AstraZeneca and Daiichi Sankyo HER2-targeting drug/antibody conjugate garnered headlines at the European Society for medical Oncology meeting last week, posting wins in metastatic HER2+ breast cancer, advanced gastric cancer, and non-small cell lung cancer. Read More
BeyondSpring Pharmaceuticals’ lung cancer drug plinabulin showed statistically significant improvement in overall survival in its phase 3 trial conducted in China. Read More
Pfizer-BioNTech’s COVID-19 vaccine for kids age five to 11 years appears ready for prime time as the first results from the companies’ trial of a COVID-19 vaccine in this age group are released. Read More
The data showed that the booster vaccination, administered to adults two years after the initial vaccination, induced a strong immune response within seven days. Read More
Amgen reported that adding its Vectibix (panitumumab) antibody to a cell proliferation blocker more than doubled response rates compared to the blocker alone in patients withKRAS G12C-mutated advanced colorectal cancer (CRC). Read More